|
|
Latest Prostate Cancer News
Death from Other Causes Among Men with Early-stage Prostate Cancer (8/26/2010)
Among men with early-stage prostate cancer, assessment of other health problems may help guide prostate cancer treatment decisions; men who are likely to die of causes other than prostate cancer may not benefit from aggressive prostate cancer treatment. These findings were published in the Archives of Internal Medicine.
Provenge® for Hormone-refractory Prostate Cancer (8/11/2010)
Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine.
Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.
Statins May Reduce Risk of Prostate Cancer Recurrence (7/2/2010)
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.
Prostate Cancer News By Topic
Prostate Cancer - Early Stage I-II (A-B)Death from Other Causes Among Men with Early-stage Prostate Cancer (8/26/2010)
Among men with early-stage prostate cancer, assessment of other health problems may help guide prostate cancer treatment decisions; men who are likely to die of causes other than prostate cancer may not benefit from aggressive prostate cancer treatment. These findings were published in the Archives of Internal Medicine.
Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.
Statins May Reduce Risk of Prostate Cancer Recurrence (7/2/2010)
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.
Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (6/30/2010)
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.
External Beam Radiation Raises Risk of Hip Fracture in Prostate Cancer (6/8/2010)
Men treated with external beam radiation therapy for prostate cancer may have an increased risk of hip fracture, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association.
Prostate Cancer - Locally Advanced Stage III (C)Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.
Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (6/8/2010)
The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Prostate Cancer and the Increased Risk of Blood Clots (4/23/2010)
Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.
Neoadjuvant Chemotherapy for High-risk Localized Prostate Cancer Is Safe and Effective (3/19/2010)
Neoadjuvant treatment with Taxotere® (docetaxel) and Emcyt® (estramustine) for high-risk localized prostate cancer appears to be safe and produces promising responses compared with standard treatment, according to the results of a Phase III randomized study presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
Prostate Cancer - Metastatic Stage IV (D)Provenge® for Hormone-refractory Prostate Cancer (8/11/2010)
Among men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) improves survival by roughly four months. The findings from this Phase III study were recently published in The New England Journal of Medicine.
Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.
Denosumab More Effective Than Zometa® in Prostate Cancer Patients with Bone Metastases (6/7/2010)
Among men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Prostate Cancer and the Increased Risk of Blood Clots (4/23/2010)
Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.
Targeted Agents plus Chemotherapy Effective for Hormone-refractory Prostate Cancer (4/7/2010)
The combination of Avastin® (bevacizumab), Thalomid® (thalidomide), and Taxotere® (docetaxel) is highly active in hormone-refractory prostate cancer, according to the results of a study published early online in the Journal of Clinical Oncology.
Prostate Cancer - Refractory/RecurrentJevtana Approved for Hormone-refractory Prostate Cancer (6/21/2010)
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.
Denosumab More Effective Than Zometa® in Prostate Cancer Patients with Bone Metastases (6/7/2010)
Among men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Provenge Approved for Advanced Prostate Cancer (4/30/2010)
Provenge® (sipuleucel-T), a type of immunotherapy, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of asymptomatic or minimally symptomatic, metastatic, hormone-refractory prostate cancer.
Investigational Drug Shows Activity in Advanced Prostate Cancer (4/26/2010)
An investigational anti-androgen drug called MDV3100 has shown encouraging anti-tumor activity in patients with progressive, metastatic, hormone-resistant prostate cancer, according to the preliminary results of a study published early online in the Lancet.
Prostate Cancer and the Increased Risk of Blood Clots (4/23/2010)
Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.
|
|
